Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA
Open Access
- 17 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (5) , 932-940
Abstract
Objective. To assess the potential of metastasin S100A4 as a biological marker in patients with RA. Methods. A total of 87 unselected patients with established RA (disease duration 2–44 years) and treated with MTX and infliximab at a single rheumatology centre were included in a cross-sectional study. Radiographs of hands and feet were taken prior to infliximab treatment and at inclusion (time interval 48 ± 27 months) and scored for the radiographic damage. S100A4 levels were analysed in relation to radiographic damage, clinical disease activity (DAS-28), inflammation (IL-6, CRP, ESR), bone and cartilage markers [MMP-3, COMP, C-telopeptide of type I collagen (CTX-I)] and proto-oncogenes [survivin, insulin-like growth factor 1 (IGF-1), Flt3 ligand]. Results. High levels of S100A4 were associated with severe radiographic damage (OR = 3.40, P = 0.025), non-response to infliximab (OR = 4.63, P = 0.003), presence of antibodies to infliximab (OR = 6.24, P = 0.003) and high levels of Flt3 ligand (OR = 2.73, P = 0.04). Regression analysis showed that high S100A4 was predictive for radiographic progression during infliximab treatment [positive predictive value (PPV) 0.68, P = 0.05]. Low levels of S100A4 were associated with response to infliximab (OR = 2.67, P = 0.049), clinical remission (OR = 4.01, P = 0.0047) and negative RF (OR = 9.22, P = 0.0047). S100A4 correlated with survivin (r = 0.71, P > 0.0001). Conclusion. S100A4 levels are increased in proportion to radiographic damage and its further progression in RA patients. High S100A4 levels were associated with a poor clinical response to infliximab and high rate of anti-infliximab antibodies. The finding of a correlation between S100A4 and survivin and Flt3 ligand suggests that these proteins may represent a new cluster of biomarkers predicting radiographic progression and poor treatment response in RA patients.Keywords
This publication has 47 references indexed in Scilit:
- Autoimmunity and hematologic malignancies: associations and mechanismsLeukemia & Lymphoma, 2009
- Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by SubtypeJNCI: Journal of the National Cancer Institute, 2006
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2005
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnnals of the Rheumatic Diseases, 2005
- Risk of lymphoma in patients with RA treated with anti-TNFα agentsAnnals of the Rheumatic Diseases, 2005
- Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patientsArthritis & Rheumatism, 2004
- Epstein‐Barr virus load in the peripheral blood of patients with rheumatoid arthritis: Accurate quantification using real‐time polymerase chain reactionArthritis & Rheumatism, 2003
- Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ, 1998
- Incidence of Cancer among Men with the Felty SyndromeAnnals of Internal Medicine, 1994
- Epstein‐barr virusArthritis & Rheumatism, 1981